Literature DB >> 8893728

Attenuation of acute and chronic damage following traumatic brain injury in copper, zinc-superoxide dismutase transgenic mice.

S Mikawa1, H Kinouchi, H Kamii, G T Gobbel, S F Chen, E Carlson, C J Epstein, P H Chan.   

Abstract

To elucidate the role of oxygen-derived free radicals and superoxide dismutase in traumatic brain injury (TBI), blood-brain barrier (BBB) permeability, brain edema, behavioral function, and necrotic cavity volume (CV) were evaluated after TBI using nontransgenic (nTg) mice and heterozygous and homozygous transgenic (Tg) mice with a 1.5- (Tg 1.5x), 3.1-(Tg3.1x) and five- (Tg5x) fold increase in human copper, zinc-superoxide dismutase (CuZn-SOD) activity. Traumatic brain injury was produced by the weight-drop method. Evans blue dye leakage 4 hours after injury was attenuated in a CuZn-SOD dose-dependent manner with decreases of 18.6%, 40.9%, and 48.8%, in the Tg1.5x, Tg3.1x, and Tg5x groups, respectively. The water content 6 hours after injury in the Tg3.1x (79.64%) and Tg5x (79.45%) groups was significantly lower than in nTg mice (81.37%). There was an initial decrease in body weight and in motor performance, as measured by beam walk and beam balance tasks undertaken 1 day after TBI. However, the average reduction in beam balance and beam walk performance deficits and changes in body weight postinjury were significantly ameliorated in Tg mice. The CV was significantly smaller in Tg mice than in nTg mice (p < 0.01). These results indicate that superoxide radicals play a deleterious role following TBI. Furthermore, Tg mice provide a useful model for demonstrating the beneficial role of an antioxidant enzyme in TBI without the confounding effect of pharmacokinetics, toxicity, and BBB permeability associated with exogenous agents.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8893728     DOI: 10.3171/jns.1996.85.5.0885

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  33 in total

1.  Neuroprotective potential of ionotropic glutamate receptor antagonists.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Neurotox Res       Date:  2002-03       Impact factor: 3.911

Review 2.  Therapies targeting lipid peroxidation in traumatic brain injury.

Authors:  Tamil Selvan Anthonymuthu; Elizabeth Megan Kenny; Hülya Bayır
Journal:  Brain Res       Date:  2016-02-10       Impact factor: 3.252

Review 3.  Antioxidant therapies for traumatic brain injury.

Authors:  Edward D Hall; Radhika A Vaishnav; Ayman G Mustafa
Journal:  Neurotherapeutics       Date:  2010-01       Impact factor: 7.620

4.  Circulating levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases during Japanese encephalitis virus infection.

Authors:  Vibha Shukla; Akhalesh Kumar Shakya; Mukti Shukla; Niraj Kumari; Narendra Krishnani; T N Dhole; Usha Kant Misra
Journal:  Virusdisease       Date:  2016-01-19

Review 5.  Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment.

Authors:  B Halliwell
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

6.  Mitochondrial susceptibility to oxidative stress exacerbates cerebral infarction that follows permanent focal cerebral ischemia in mutant mice with manganese superoxide dismutase deficiency.

Authors:  K Murakami; T Kondo; M Kawase; Y Li; S Sato; S F Chen; P H Chan
Journal:  J Neurosci       Date:  1998-01-01       Impact factor: 6.167

7.  Experimental traumatic brain injury.

Authors:  Christiane Albert-Weissenberger; Anna-Leena Sirén
Journal:  Exp Transl Stroke Med       Date:  2010-08-13

8.  Sulforaphane improves cognitive function administered following traumatic brain injury.

Authors:  Pramod K Dash; Jing Zhao; Sara A Orsi; Min Zhang; Anthony N Moore
Journal:  Neurosci Lett       Date:  2009-04-15       Impact factor: 3.046

9.  Differential regulation of CuZnSOD expression in rat brain by acute and/or chronic stress.

Authors:  Dragana Filipović; Snezana B Pajović
Journal:  Cell Mol Neurobiol       Date:  2009-03-13       Impact factor: 5.046

Review 10.  Drug targets for traumatic brain injury from poly(ADP-ribose)polymerase pathway modulation.

Authors:  Valerie C Besson
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.